A Phase III, Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients with Metastatic Prostate Cancer Commencing Hormonal Therapy

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• C. Sweeney, W. M. Dugan II, R. Dreicer, F. Chu, G. Parks, K. Baker, D. Reed, K. Jansz, J. Zadra, C. T. Yiannoutsos. A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC): Hoosier Oncology Group GU02-41. Accepted to the ASCO Annual Meeting, June 4-8, 2010, Chicago, IL. J Clin Oncol 28, 2010 (suppl; abstr e15000)
• J. Sharma, C. T. Yiannoutsos, N. M. Hahn, C. Sweeney. Prognostic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer: Hoosier Oncology Group GU02-41. Accepted to the general poster session at the ASCO Annual Meeting June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 4594). See abstract.

Manuscripts/Articles:

• Hahn NM, Yiannoutsos, CT, Kirkpatrick K, Sharma J, Sweeney, CJ. Failure to suppress markers of bone turnover on first line hormonal therapy for metastatic prostate cancer is associated with shorter time to skeletal related event: Hoosier Oncology Group GU02-41. Clin Genitourin Cancer 2014Fe;12(1):33-40.e4 doi: 10.1016/j.clgc.2013.07.002. Epub 2013 Oct 12.